Sarepta Therapeutics (SRPT) fell despite reporting good results

Carillon Tower Counselors“Carillon Eagle Mid Cap Growth Fund” in the second quarter of the second quarter of 2025. It could be a copy of the message It was downloaded here. Medium stocks flourished in the second quarter, which led to a strong recovery. The Russian MidCap growth index (18.20 % increase) outperformed the Russian MidCap® value index (an increase of 5.34 %) in the quarter. In addition, you can check the 5 best holdings of the box to determine its best choices for 2025.

In the investor’s speech in the second quarter of 2025, the Carillon Eagle Mid Cap has highlighted stocks like Sarepta Therapeutics, Inc. (Nasdaq:SRPT). Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biomedical pharmaceutical company. The return of two months of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) 11.69 %, and has lost 86.53 % of its value over the past 52 weeks. On September 02, 2025, Sarepta Therapeutics closed, Inc.

Carillon Eagle Mid Cap Growth Fund is following the following regarding Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in the investor’s speech in the second quarter 2025:

“Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Development of targeted drugs from RNA and genetic treatments for rare neurological diseases. The company informed the quarterly revenues that exceeded expectations, but it recorded a greater loss than the one -expected share and reviewed its sales expectations for 2025. The stock was sold sharply after the death of a second patient from the failure of the acute liver after he was treated with the highlands, and his genetic treatment for patients suffering from muscular degeneration.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is not listed in our list 30 shares more popular among hedge boxes. According to our database, 41 Nasdaq: SRPT at the end of the second quarter, which was 47 in the previous quarter. While we acknowledge the capabilities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) as an investment, we believe that some artificial intelligence shares provide greater potential and carry less risks on the downside. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

in Another articleWe covered Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and share the Jim Cramer list that he talked about. In addition, please review Hedgement funds investor Q2 2025 A page for more investor messages from hedge funds and other prominent investors.